Llwytho...
A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report(†)
BACKGROUND: A phase I trial of veliparib (ABT-888), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, and temozolomide (TMZ) was conducted in children with recurrent brain tumors to (i) estimate the maximum tolerated doses (MTDs) or recommended phase II doses (RP2Ds) of veliparib and TMZ; (ii) d...
Wedi'i Gadw mewn:
Cyhoeddwyd yn: | Neuro Oncol |
---|---|
Prif Awduron: | , , , , , , , , , , , , , , , , , |
Fformat: | Artigo |
Iaith: | Inglês |
Cyhoeddwyd: |
Oxford University Press
2014
|
Pynciau: | |
Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4232081/ https://ncbi.nlm.nih.gov/pubmed/24908656 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou103 |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|